Hepcidin (HAMP): Master Iron Regulatory Hormone Controlling Ferroportin, Anemia of Chronic Disease, and Hereditary Hemochromatosis in Research

# Hepcidin (HAMP): Master Iron Regulatory Hormone Controlling Ferroportin, Anemia of Chronic Disease, and Hereditary Hemochromatosis in Research

Introduction

Iron is simultaneously essential for life and toxic in excess. As a cofactor for hemoglobin, myoglobin, cytochromes, ribonucleotide reductase, and dozens of enzymes, iron underpins oxygen transport, mitochondrial respiration, and DNA synthesis. Yet free iron participates in Fenton chemistry, generating hydroxyl radicals that damage DNA, proteins, and lipids. Vertebrates have evolved an exquisitely regulated system to maintain iron within safe and functional ranges — and the master control hormone of this system is hepcidin.

Hepcidin, encoded by the HAMP gene, is a 25-amino-acid defensin-like peptide produced predominantly by hepatocytes. Its primary effector is ferroportin (SLC40A1/FPN1), the only known cellular iron export channel. By binding ferroportin and triggering its internalization and lysosomal degradation, hepcidin simultaneously prevents iron absorption in the duodenum, iron release from macrophage iron stores, and iron export from hepatocytes — reducing circulating iron.

This elegant mechanism underlies two major classes of human disease. When hepcidin production is insufficient (as in type 1 hereditary hemochromatosis due to HFE mutations, or type 2 juvenile hemochromatosis due to hemojuvelin mutations), unchecked ferroportin activity leads to iron overload, organ damage, and eventually cirrhosis, diabetes, and cardiomyopathy. When hepcidin is chronically elevated (as in chronic inflammation, cancer, chronic kidney disease), excessive ferroportin suppression traps iron in macrophages and prevents erythropoiesis despite adequate iron stores — the mechanism of anemia of chronic disease (ACD), also termed anemia of inflammation.

Understanding hepcidin biology is essential for researchers studying iron metabolism, anemia, hemochromatosis, and the intersection of inflammation with erythropoiesis.

Discovery and Initial Characterization

Hepcidin was identified in 2000-2001 through three independent routes, each naming it differently before convergence on "hepcidin."

Krause et al. (2000) isolated a small cysteine-rich antimicrobial peptide from human urine during a screen for novel defensin-like proteins. They named it LEAP-1 (Liver-Expressed Antimicrobial Peptide-1) due to its hepatic expression and in vitro bactericidal activity at high concentrations (FEBS Letters,).

Park et al. (2001) independently identified the same peptide from human blood ultrafiltrate, naming it hepcidin (hepatic + bactericidal). Their mass spectrometry analysis identified three naturally occurring forms: hepcidin-25 (the predominant and active form), hepcidin-20, and hepcidin-22 (Journal of Biological Chemistry, PMID 11294876).

The iron-regulatory function was not immediately apparent from these antimicrobial discovery papers. The critical link came when Pigeon et al. (2001) showed that dietary iron loading in mice dramatically induced hepatic hepcidin mRNA (Journal of Biological Chemistry,), and Nicolas et al. (2001, 2002) demonstrated that hepcidin knockout mice developed massive iron overload resembling hemochromatosis, while hepcidin-overexpressing transgenic mice developed severe iron-deficiency anemia despite normal dietary iron intake — proving bidirectional regulatory control (PNAS, PMID 11606777; Nature Genetics,).

The mechanism connecting hepcidin to iron transport was finally established by Nemeth et al. (2004) in a landmark Science paper (PMID 15514116): hepcidin directly binds ferroportin, inducing its phosphorylation, internalization, and lysosomal degradation — the first molecular explanation for how a circulating hormone regulates cellular iron export.

Gene Structure and Peptide Biochemistry

The HAMP gene (chromosome 19q13.12) spans approximately 2.5 kb and consists of three exons encoding an 84-amino-acid prepropeptide:

• •Signal peptide (24 aa): directs co-translational insertion into the ER
• •Prodomain (35 aa): facilitates folding; cleaved by furin-like proprotein convertases
• •Mature hepcidin-25 (25 aa): the circulating active form

Structural features of hepcidin-25:

• •25 amino acids with a remarkably compact structure
• •8 cysteines forming 4 disulfide bonds in a ladder-like arrangement (Cys1-Cys8, Cys2-Cys7, Cys3-Cys6, Cys4-Cys5 — a "vicinal" disulfide between adjacent cysteines 4-5 is unusual)
• •N-terminal region: forms a β-hairpin structure critical for ferroportin binding
• •The first 5 amino acids (DTHFP) at the N-terminus are essential for ferroportin binding and biological activity
• •Molecular weight: ~2.8 kDa

Crystal structure analysis and NMR have confirmed the distorted β-sheet conformation stabilized by the disulfide ladder. The vicinal Cys4-Cys5 bond is biochemically unusual and creates conformational rigidity at the ferroportin-binding face.

Hepcidin-20 and hepcidin-22 lack N-terminal residues (5 and 3, respectively) and cannot bind ferroportin efficiently — they are inactive regarding iron regulation but retain some antimicrobial activity.

Ferroportin: The Sole Target and Iron Export Portal

Ferroportin (FPN1/SLC40A1) is a 12-transmembrane domain iron transporter expressed on:

• •Duodenal enterocytes (basolateral membrane): exports absorbed dietary iron into portal circulation
• •Macrophages (surface): exports recycled iron from hemoglobin degradation of senescent erythrocytes
• •Hepatocytes: exports stored iron
• •Placental syncytiotrophoblasts: maternal-to-fetal iron transfer

Ferroportin is the only known mammalian iron exporter. Its critical importance is demonstrated by the fact that no functional ferroportin ortholog deletion is viable in mice — early embryonic lethality occurs because placental iron transfer fails.

Hepcidin-Ferroportin Interaction Mechanism

Hepcidin binds to an extracellular loop of ferroportin with nanomolar affinity (Kd ~1-10 nM for hepcidin-25). This binding event:

1. Induces a conformational change in ferroportin

2. Triggers ferroportin ubiquitination (via JAK2 and potentially other kinases)

3. Drives clathrin-mediated endocytosis of the hepcidin-ferroportin complex

4. Targets the complex to lysosomes for degradation

5. Intracellular iron becomes trapped — it cannot be exported

The result is a dose-dependent, reversible block on cellular iron export. When hepcidin levels fall, new ferroportin is synthesized (from constitutive mRNA), restoring export capacity within hours.

The crystal structure of the hepcidin-ferroportin complex (Billesbølle et al., 2020, Nature, PMID 32814339) revealed that hepcidin inserts into the outward-open conformation of ferroportin's central cavity — providing a structural basis for drug design targeting this interaction.

Regulation of Hepcidin Production

Hepcidin expression is controlled by four major input signals that reflect the body's iron needs and inflammatory status.

1. Iron Stores (Positive Regulator)

High hepatic and systemic iron upregulates hepcidin via the BMP/SMAD pathway:

• •BMP6 (and BMP2) are produced by liver sinusoidal endothelial cells in response to hepatic iron loading
• •BMP6 binds BMP receptor complexes (BMPR1/BMPR2) on hepatocytes
• •Hemojuvelin (HJV/RGMc) is a GPI-anchored co-receptor that dramatically amplifies BMP signaling in hepatocytes
• •BMP receptor activation phosphorylates SMAD1/5/8 → SMAD4 complex → nuclear translocation → HAMP transcription
• •Serum transferrin saturation is sensed by HFE (the hemochromatosis protein) and TfR1/TfR2: at high transferrin saturation, HFE dissociates from TfR1 and can interact with TfR2; TfR2 then amplifies BMP/SMAD signaling to increase hepcidin

2. Erythropoietic Demand (Negative Regulator)

When erythropoiesis is activated (e.g., after hemorrhage, hemolysis, hypoxia, EPO administration), hepcidin is suppressed to mobilize iron for red cell production:

• •Erythropoiesis releases erythroferrone (ERFE) from erythroblasts
• •ERFE acts as a "BMP trap" — sequestering BMP6 and BMP2, preventing their binding to hepatocyte receptors
• •Reduced BMP signaling → reduced SMAD phosphorylation → reduced hepcidin (Kautz et al., 2014, Nature Genetics, PMID 24770641)
• •GDF15 and TWSG1 (produced by erythroblasts) may provide additional hepcidin-suppressive signals in thalassemia and other ineffective erythropoiesis conditions

3. Hypoxia (Negative Regulator)

Hypoxia suppresses hepcidin through multiple mechanisms:

• •HIF-2α upregulates erythropoietin → erythroferrone pathway
• •HIF-2α directly activates duodenal SLC11A2 (DMT1) and DCYTB expression, increasing iron absorption regardless of hepcidin (intestinal pathway)
• •TMPRSS6 (matriptase-2), a serine protease, cleaves membrane hemojuvelin, reducing BMP co-receptor signaling and thus hepcidin — TMPRSS6 is upregulated by iron deficiency/hypoxia

4. Inflammation (Positive Regulator — ACD Mechanism)

Inflammatory cytokines, particularly IL-6, dramatically upregulate hepcidin:

• •IL-6 → JAK1/2-STAT3 → STAT3 binding to HAMP promoter → hepcidin transcription (Nemeth et al., 2004, Blood,)
• •IL-1β, LPS, and activin B can also upregulate hepcidin via alternative pathways
• •The resulting high hepcidin → ferroportin degradation → iron trapped in macrophages and liver → hypoferremia → restricted iron for bacterial growth (nutritional immunity) AND restricted iron for erythropoiesis → anemia of chronic disease

This IL-6/hepcidin axis is the molecular mechanism underlying ACD in rheumatoid arthritis, inflammatory bowel disease, cancer, chronic infection, and critical illness.

Hereditary Hemochromatosis: Insufficient Hepcidin

Hereditary hemochromatosis (HH) is the most common inherited iron overload disorder, caused by insufficient hepcidin or ferroportin resistance to hepcidin. Multiple genetic subtypes exist:

The C282Y mutation in HFE (substitution of a cysteine critical for MHC class I-like folding) prevents HFE from reaching the cell surface and interacting with TfR1, impairing iron sensing and resulting in inappropriately low hepcidin for the degree of iron loading. Approximately 1 in 200-300 Northern Europeans is homozygous for C282Y, though penetrance is incomplete — fewer than 30% of homozygous males develop clinical iron overload, with lower penetrance in females due to menstrual iron losses.

Untreated hemochromatosis leads to progressive iron deposition in the liver (cirrhosis, hepatocellular carcinoma), pancreas (diabetes mellitus, "bronze diabetes"), heart (cardiomyopathy, arrhythmia), joints (arthropathy), skin (hyperpigmentation, "bronze diabetes" name origin), and pituitary/gonads (hypogonadism). Treatment remains therapeutic phlebotomy — removing iron-rich red cells — which remains highly effective when initiated before cirrhosis.

Anemia of Chronic Disease: Excess Hepcidin

Anemia of chronic disease (ACD), also termed anemia of inflammation (AI), is the second most common anemia worldwide after iron-deficiency anemia. It occurs in patients with:

• •Rheumatoid arthritis, lupus, IBD
• •Cancer (tumor-associated inflammation)
• •Chronic infections (HIV, tuberculosis, endocarditis)
• •Chronic kidney disease (CKD)
• •Heart failure
• •Critical illness/ICU patients

The hallmark is anemia with low serum iron and transferrin saturation despite normal or elevated serum ferritin (reflecting trapped iron in macrophages). This hypoferremia is primarily mediated by hepcidin-driven ferroportin degradation on macrophages that have recently phagocytosed senescent erythrocytes.

In CKD specifically, hepcidin accumulates due to reduced renal clearance and inflammation-driven IL-6 induction, creating a double hit on ferroportin and severely impairing iron utilization for erythropoiesis even when patients receive intravenous iron supplementation.

Iron Absorption: The Duodenal Circuit

Dietary iron exists as heme iron (from animal hemoglobin/myoglobin, absorbed by HCP1/FLVCR2) and non-heme iron (Fe³⁺, the majority of plant iron). The non-heme absorption pathway:

1. Luminal DCYTB (duodenal cytochrome b) reduces Fe³⁺ → Fe²⁺ on the apical surface

2. DMT1 (SLC11A2) imports Fe²⁺ across the apical enterocyte membrane

3. Iron traverses the enterocyte (some stored as ferritin)

4. Ferroportin on the basolateral surface exports Fe²⁺ into the portal circulation

5. Hephaestin (a ceruloplasmin-like ferroxidase) oxidizes Fe²⁺ → Fe³⁺ for binding to transferrin

6. Transferrin-bound iron circulates to tissues

Hepcidin acts at step 4: degrading basolateral ferroportin reduces iron export and effectively caps absorption regardless of intake. This prevents excessive iron absorption in hemochromatosis if therapeutic hepcidin were administered — and explains why hepcidin mimetics are being developed as treatments.

Macrophage Iron Recycling: The Dominant Daily Flux

Daily erythropoiesis requires ~20 mg iron, but dietary absorption provides only ~1-2 mg/day. The vast majority (~18-19 mg/day) comes from macrophage recycling of senescent red cells:

1. Splenic and hepatic macrophages phagocytose ~120-day-old erythrocytes

2. HO-1 (heme oxygenase-1) degrades hemoglobin heme → biliverdin + CO + Fe²⁺

3. Fe²⁺ accumulates in macrophage cytoplasm

4. Ferroportin exports Fe²⁺ → ceruloplasmin oxidizes → transferrin binds

5. Transferrin delivers iron to erythroblasts in bone marrow

Hepcidin-induced ferroportin degradation on macrophages blocks step 4, trapping recycled iron. This is the primary mechanism of hypoferremia in ACD — macrophages physically contain iron but cannot release it.

Therapeutic Targeting of Hepcidin Biology

Hepcidin Mimetics (for Hemochromatosis and Iron-Loading Anemias)

Minihepcidins are short N-terminal peptide fragments of hepcidin that retain ferroportin-binding activity at lower doses. Developed by Preza et al. (2011, Journal of Clinical Investigation, PMID 21364284), PR65 and related compounds reduced iron overload in Hfe−/− mice when administered subcutaneously. Phase I development is ongoing.

LJPC-401 (synthetic hepcidin-20 analog) was tested in Phase II for hereditary hemochromatosis and polycythemia vera — modest iron lowering at tested doses, development uncertain.

PTG-300 (rusfertide) is a hepcidin mimetic being investigated in polycythemia vera (PV), where reducing iron availability limits erythrocytosis. Phase III REVIVE trial ongoing.

Anti-Hepcidin Approaches (for Anemia of Chronic Disease)

Lexaptepid (NOX-H94) is a Spiegelmer (L-oligonucleotide aptamer) binding and neutralizing hepcidin. Phase II studies in ACD of chronic kidney disease and cancer showed increased serum iron and hemoglobin (van Eijk, Schwoebel et al., 2014, Blood, PMID 25163699).

Monoclonal antibodies against hepcidin (LY2787106, AB79) have entered clinical evaluation for cancer-associated anemia and ACD with encouraging early results.

Anti-BMP signaling (reducing hepcidin production):

• •Luspatercept (REBLOZYL) is an activin receptor ligand trap (ActRIIB-IgG1-Fc) that targets SMAD2/3 signaling in erythroblasts, reducing ineffective erythropoiesis — approved for β-thalassemia and MDS. It also suppresses hepcidin somewhat via erythroferrone-like mechanisms.
• •Sotatercept (precursor to luspatercept concept) showed hepcidin reduction in clinical trials.
• •ALK2 inhibitors (ACVR1 inhibitors): block BMP-SMAD signaling specifically; reduce hepcidin. Being explored for fibrodysplasia ossificans progressiva overlap.

TMPRSS6 Targeting (Reduce Hepcidin via Hemojuvelin)

TMPRSS6 siRNA/ASO approaches: silencing matriptase-2 increases hemojuvelin → BMP signaling → hepcidin → reduce iron overload. Shown effective in beta-thalassemia and hemochromatosis mouse models; clinical investigation ongoing (SLN124 by Silence Therapeutics in Phase II for polycythemia vera).

Erythropoiesis-Stimulating Agents (ESAs) and Their Interaction

EPO (erythropoietin) and ESAs work partly by stimulating erythroferrone release from erythroblasts, which suppresses hepcidin and mobilizes iron. In CKD patients on ESAs, iron supplementation is often required because mobilized iron is rapidly consumed by stimulated erythropoiesis — a scenario complicated by high baseline hepcidin in CKD.

Serum Hepcidin as a Biomarker

Quantification of serum hepcidin by mass spectrometry (LC-MS/MS) or ELISA enables distinction of:

• •Iron deficiency (low hepcidin) vs. ACD (high hepcidin) — critical for treatment planning
• •Response to anti-inflammatory therapy in ACD
• •Hemochromatosis subtype assessment
• •Iron supplementation strategy in CKD and oncology patients

Normal serum hepcidin range: approximately 2-20 nmol/L in adults (assay-dependent). Diurnal variation exists with a morning peak.

Research Tools and Models

Current Research Frontiers

Hepcidin in Acute Inflammation and Sepsis

Hepcidin rises within hours of bacterial infection or LPS challenge, creating acute hypoferremia. This nutritional immunity response restricts iron availability for bacterial growth (many pathogens require iron). However, sustained hepcidin elevation in sepsis contributes to anemia of critical illness — creating tension between antimicrobial benefit and erythropoietic cost.

Hepcidin in Cardiovascular Disease

Several population studies have associated high hepcidin with worse cardiovascular outcomes, potentially through iron-restriction effects on cardiac and vascular function. Conversely, hepcidin may protect by limiting iron-mediated oxidative stress. The directional relationship remains contested.

Hepcidin and SARS-CoV-2 / COVID-19

COVID-19 is associated with marked hypoferremia and anemia, partly driven by IL-6-stimulated hepcidin. Severe COVID-19 patients show markedly elevated serum hepcidin. Hepcidin-directed therapies were proposed during the pandemic but not clinically validated.

Hepcidin in Cancer Biology

Iron is required for rapidly dividing cancer cells. Tumor-associated inflammation elevates hepcidin, creating systemic iron restriction — but tumors often upregulate transferrin receptor (TfR1) to compete for circulating iron. Anti-hepcidin strategies theoretically increase systemic iron but may also fuel tumor growth — a complex therapeutic calculus requiring tumor-specific iron biology understanding.

Ferroptosis and Hepcidin

Ferroptosis — iron-dependent regulated cell death via lipid peroxidation — is increasingly recognized in cancer and neurodegeneration. Hepcidin-controlled systemic iron levels influence cellular iron availability and therefore ferroptosis susceptibility, suggesting hepcidin modulation could influence ferroptosis in tissues.

Non-Hepatic Hepcidin Production

While the liver is the primary source, hepcidin mRNA and protein are expressed in macrophages, brain, kidney, heart, and adipose tissue. The function of locally produced hepcidin — potentially acting in paracrine fashion on local ferroportin without altering systemic iron — is an emerging research area.

Conclusion

Hepcidin occupies a position analogous to insulin in glucose metabolism: it is a single peptide hormone that integrates multiple afferent signals — iron stores, erythropoietic demand, hypoxia, and inflammation — to regulate a fundamental nutrient. The elegance of the hepcidin-ferroportin axis, in which one peptide binding to one receptor simultaneously controls iron absorption, iron recycling, and iron storage, rivals any biological system in its parsimony.

For researchers, hepcidin offers a tractable quantitative target with validated biomarkers, well-characterized genetic disease models (hemochromatosis knockouts, thalassemia models), and a growing pharmacological toolkit ranging from synthetic minihepcidins to siRNA approaches. The therapeutic frontier — using hepcidin modulation to treat hemochromatosis, ACD, polycythemia vera, thalassemia, and potentially cancer — represents one of the most active areas in translational hematology.

Key Research Citations

2. Park CH, et al. (2001). Hepcidin, a urinary antimicrobial peptide synthesized in the liver. Journal of Biological Chemistry, 276(11), 7806-7810. PMID: 11294876

4. Nicolas G, et al. (2002). Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. PNAS, 99(7), 4596-4601. PMID: 11930005

5. Nemeth E, et al. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 306(5704), 2090-2093. PMID: 15514116

6. Nemeth E, et al. (2004). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation, 113(9), 1271-1276. PMID: 15124018

7. Kautz L, et al. (2014). Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature Genetics, 46(7), 678-684. PMID: 24770641

8. Billesbølle CB, et al. (2020). Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms. Nature, 586(7831), 807-811. PMID: 32814339

9. Preza GC, et al. (2011). Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. Journal of Clinical Investigation, 121(12), 4880-4888. PMID: 21364284

10. Feder JN, et al. (1996). A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics, 13(4), 399-408. PMID: 8696333

---

This article is intended for Research Use Only (RUO). Hepcidin-related research tools and compounds described herein are not approved for human therapeutic use outside of specifically indicated clinical applications. All research involving hepcidin modulation must comply with applicable institutional and regulatory guidelines. This content does not constitute medical advice.